Probi
207 SEK -6.33%Be the first to follow this company
Probi is a biotechnology company. The company is particularly focused on the research and development of probiotics, a bacterium that is found in the human intestinal system. The research areas within the company include the gastrointestinal, immune system, metabolic syndrome, and stress and recovery. The company's customers include larger corporate customers active in the food industry. The company was founded in 1991 and is headquartered in Lund.
Revenue
627.69M
EBIT %
1.8 %
P/E
139.86
Dividend yield-%
0.63 %
Target price
-
Recommendation
-
Updated
-
NASDAQ Stockholm
PROB
Daily low / high price
200 / 220
SEK
Market cap
2.36B SEK
Turnover
401.76K SEK
Volume
1.9K
Latest videos
Financial calendar
Interim report
2024-04-23
General meeting
2024-05-07
Annual dividend
2024-05-08
Interim report
2024-07-16
Interim report
2024-10-22
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Symrise | 69.6 % | 69.6 % |
Fjärde AP-fonden | 9.3 % | 9.3 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Presentation of Probi's Q1 Report 2024
Presentation av Probis Q1-rapport 2024
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools